Evidence map›Paper›PMID 39854369›Full record

ArticlePloS one2025

Weight trajectories in aging humanized APOE mice with translational validity to human Alzheimer's risk population: A retrospective analysis.

Francesca Vitali, Jean-Paul Wiegand, Lillian Parker-Halstead, Allan Tucker, Roberta Diaz Brinton

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Francesca VitaliCenter for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, Arizona, United States of America.ORCID 0000-0003-2916-6402
Jean-Paul WiegandCenter for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, Arizona, United States of America.
Lillian Parker-HalsteadCenter for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, Arizona, United States of America.
Allan TuckerDepartment of Computer Science, Brunel University London, Uxbridge, United Kingdom.
Roberta Diaz BrintonCenter for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, Arizona, United States of America.

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERTA EILEEN BRINTON · 2006 to 2026
$53.7M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal EndophenotypeR01AG057931 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2022
$6.0M
Translational research in Alzheimer’s Disease and Related Dementias (TRADD)T32AG061897 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN · 2018 to 2022
$1.3M
NIA NIH HHS P01 AG026572NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG057931NIA NIH HHS T32 AG061897
6 · The paper itself

Abstract

Translational validity of mouse models of Alzheimer's disease (AD) is variable. Because change in weight is a well-documented precursor of AD, we investigated whether diversity of human AD risk weight phenotypes was evident in a longitudinally characterized cohort of 1,196 female and male humanized APOE (hAPOE) mice, monitored up to 28 months of age which is equivalent to 81 human years. Autoregressive Hidden Markov Model (AHMM) incorporating age, sex, and APOE genotype was employed to identify emergent weight trajectories and phenotypes. In the hAPOE-AD mouse cohort, five distinct weight trajectories emerged: three trajectories were associated with a weight loss phenotype (36% of mice, n = 426), one with weight gain (13% of mice, n = 152), and one trajectory of no change in weight (34% of mice, n = 403). The AHMM model findings were validated with post-hoc survival analyses, revealing differences in survival rates across the five identified phenotypes. Further validation was performed using body composition and plasma β-amyloid data from mice within the identified gain, loss and stable weight trajectories. Weight gain trajectory was associated with elevated plasma β-amyloid levels, higher body fat composition, lower survival rates and a greater proportion of APOE4/4 carriers. In contrast, weight loss was associated with greater proportion of hAPOE3/4 carriers, better survival rates and was predominantly male. The association between weight change and AD risk observed in humans was mirrored in the hAPOE-AD mouse model. Weight trajectories of APOE3/3 mice were equally distributed across weight gain, loss and stability. Surprisingly, despite genetic uniformity, comparable housing, diet and handling, distinct weight trajectories and divergence points emerged for subpopulations. These data are consistent with the heterogeneity observed in the human population for change in body weight during aging and highlight the importance of longitudinal phenotypic characterization of mouse aging to advance the translational validity of preclinical AD mouse models.

Indexed as

AgingAlzheimer DiseaseApolipoproteins EBody-Weight TrajectoryAmyloid beta-PeptidesAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicPhenotypeRetrospective StudiesWeight GainAmyloid beta-PeptidesApolipoproteins E

Identifiers

PMID39854369
PMCPMC11760569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.